Download MendeleyStructure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787.
Hirst, D.J., Bamborough, P., Al-Mahdi, N., Angell, D.C., Barnett, H.A., Baxter, A., Bit, R.A., Brown, J.A., Chung, C.W., Craggs, P.D., Davis, R.P., Demont, E.H., Ferrie, A., Gordon, L.J., Harada, I., Ho, T.C.T., Holyer, I.D., Hooper-Greenhill, E., Jones, K.L., Lindon, M.J., Lovatt, C., Lugo, D., Maller, C., McGonagle, G., Messenger, C., Mitchell, D.J., Pascoe, D.D., Patel, V.K., Patten, C., Poole, D.L., Shah, R.R., Rioja, I., Stafford, K.A.J., Tape, D., Taylor, S., Theodoulou, N.H., Tomlinson, L., Wall, I.D., Wellaway, C.R., White, G., Prinjha, R.K., Humphreys, P.G.(2024) J Med Chem
- PubMed: 38866424
- DOI: https://doi.org/10.1021/acs.jmedchem.4c00959
- Primary Citation of Related Structures:
9FBX, 9FBY - PubMed Abstract:
The bromodomain and extra terminal (BET) family of bromodomain-containing proteins are important epigenetic regulators that elicit their effect through binding histone tail N -acetyl lysine (KAc) post-translational modifications. Recognition of such markers has been implicated in a range of oncology and immune diseases and, as such, small-molecule inhibition of the BET family bromodomain-KAc protein-protein interaction has received significant interest as a therapeutic strategy, with several potential medicines under clinical evaluation. This work describes the structure- and property-based optimization of a ligand and lipophilic efficient pan-BET bromodomain inhibitor series to deliver candidate I-BET787 ( 70 ) that demonstrates efficacy in a mouse model of inflammation and suitable properties for both oral and intravenous (IV) administration. This focused two-phase explore-exploit medicinal chemistry effort delivered the candidate molecule in 3 months with less than 100 final compounds synthesized.
Organizational Affiliation:
GSK Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, U.K.
